SCHEMBL3767582

SCHEMBL3767582

O=C(Cc1ccc(Oc2ccccc2)cc1)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
KDM4E B2RXH2 3/20 0.65
HRH3 Q9Y5N1 4/20 0.59
ACHE P22303 1/20 0.49
GAA P10253 2/20 0.48
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TSHR P16473 1/20 0.47
KMT2A Q03164 1/20 0.47
USP2 O75604 1/20 0.47
ACACB O00763 1/20 0.47
ACACA Q13085 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
TPSAB1 Q15661 1/20 0.46
TPSD1 Q9BZJ3 1/20 0.46
TPSG1 Q9NRR2 1/20 0.46
HSD11B1 P28845 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3761258 0.91 KDM4E (0.61) ALDH1A1KDM4EHRH3ACHEGAA
SCHEMBL3770129 0.90 ALDH1A1 (0.80) ALDH1A1KDM4EHRH3ACHELMNA
SCHEMBL13005789 0.89 KDM4E (0.64) ALDH1A1KDM4EHRH3ACHEGAA
SCHEMBL3772641 0.88 ALDH1A1 (0.69) ALDH1A1KDM4EHRH3ACHELMNA
SCHEMBL3777237 0.87 SMN1; SMN2 (0.64) ALDH1A1KDM4EACHEGAALMNA
SCHEMBL3774296 0.85 KDM4E (0.53) ALDH1A1KDM4EHRH3ACHEGAA
SCHEMBL3767671 0.84 ALDH1A1 (0.56) ALDH1A1KDM4EHRH3ACHEGAA
SCHEMBL3775904 0.84 HRH3 (0.54) ALDH1A1KDM4EHRH3TSHRKMT2A
SCHEMBL3771283 0.83 KDM4E (0.59) ALDH1A1KDM4ETSHRKMT2AACACB
SCHEMBL3775691 0.83 ALDH1A1 (0.61) ALDH1A1KDM4EHRH3GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885KDM4E 534/4885HRH3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.